Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures

Drug Metabolism and Disposition

Volumn 32, Issue 5, 2004, Pages 512-518

  Komoroski, Bernard J ^a   Zhang, Shimin ^a   Cai, Hongbo ^b   Hutzler, J Matthew ^c,e   Frye, Reginald ^a,e,g   Tracy, Timothy S ^c,f   Strom, Stephen C ^b   Lehmann, Thomas ^b   Ang, Catharina Y W ^d   Cui, Yan Yan ^d   Venkataramanan, Raman ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

^d NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^e PFIZER INC   (United States)

^f UNIVERSITY OF FLORIDA   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; HYPERFORIN; HYPERICIN;

ARTICLE; CHRONIC DRUG ADMINISTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EXPOSURE; DRUG RESEARCH; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; HYPERICUM PERFORATUM; LIVER CELL CULTURE; PRIORITY JOURNAL; SCREENING TEST;

BICYCLO COMPOUNDS; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; ENZYME INHIBITORS; HEPATOCYTES; HUMANS; HYPERICUM; PHLOROGLUCINOL; RNA, MESSENGER; TERPENES;

EUKARYOTA; HYPERICUM; HYPERICUM PERFORATUM;

EID: 11144355476     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.32.5.512     Document Type: Article

References (25)

1. Ahmed SM, Banner NR, and Dubrey SW (2001) Low cyclosporin-A level due to Saint-John's-wort in heart transplant patients. J Heart Lung Transplant 20:795.
2. Blumenthal M (2003) Herbs continue slide in mainstream market: sales down 14 percent HerbalGram 58:71.
3. Bowen WP, Carey JE, Miah A, McMurray HF, Munday PW, James RS, Coleman RA, and Brown AM (2000) Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 28:781-788.
4. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, and Fattinger K (2000) St John's wort induces intestinal P-glycoprotein/MDRI and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68:598-604.
5. Finnstrom N, Thorn M, Loof L, and Rane A (2001) Independent patterns of cytochrome P450 gene expression in liver and blood in patients with suspected liver disease. Eur J Clin Pharmacol 57:403-409.
6. Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, Fahre J, Carrere N, and Maurel P (2001) Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 29:242-251.
7. Kostrubsky VE, Ramachandran V, Venkataramanan R, Dorko K, Esplen JE, Zhang S, Sinclair JF, Wrighton SA, and Strom SC (1999) The use of human hepatocyte cultures to study the induction of cytochrome P-450. Drug Metab Dispos 27:887-894.
8. Kostrubsky VE, Strom SC, Wood SG, Wrighton SA, Sinclair PR, and Sinclair JF (1995) Ethanol and isopentanol increase CYP3A and CYP2E in primary cultures of human hepatocytes. Arch Biochem Biophys 322:516-520.
9. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, and Melchart D (1996) St John's wort for depression - an overview and meta-analysis of randomised clinical trials. BMJ 313: 253-258.
10. Liu FF, Ang CYW, Heinze TM, Rankin JD, Beger RD, Freeman JM, and Lay JO Jr (2000) Evaluation of major active components in St. John's wort dietary supplements by high-performance liquid chromatography with photodiode array detection and electrospray mass spectrometric confirmation. J Chromatogr A 888:85-92.
11. Lowry O, Rosebrough N, Rasmussen A, Gorski JC, Hall SD, Xu L, Kaminski DL, and Cheng LK (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
12. Maurer A, Johne A, Bauer S, Brockmoller J, Donath F, Roots I, Langheinrich M, and Hubner WD (1999) Interaction of St. John's wort extract with phenprocoumon (Abstract). Eur J Clin Pharmacol 55:A55.
13. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL, and Kliewer SA (2000) St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 97:7500-7502.
14. Muller WE, Singer A, Wonnemann M, Hafner U, Rolli M, and Schafer C (1998) Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry 31 (Suppl 1):16-21.
15. Noldner M and Chatterjee S (2001) Effects of two different extracts of St. John's wort and some of their constituents on cytochrome P450 activities in rat liver microsomes. Pharmacopsychiatry 34 (Suppl 1):S108-S110.
16. Obach RS (2000) Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 294:88-95.
17. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, and Falloon J (2000) Indinavir concentrations and St. John's wort. Lancet 355:547-548.
18. Pohl RJ and Fouts JR (1980) A rapid method for assaying the metabolism of 7-ethoxyresorufin by microsomal subcellular fractions. Anal Biochem 107:150-155.
19. Sahi J, Hamilton G, Sinz M, Barros S, Huang SM, Lesko LJ, and LeCluyse EL (2000) Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes. Xenobiotica 30:273-284.
20. Strom SC, Pisarov LA, Dorko K, Thompson MT, Schuetz JD, and Schuetz EG (1996) Use of human hepatocytes to study P450 gene induction. Methods Enzymol 272:388-401.
21. Tracy TS, Rosenbluth BW, Wrighton SA, Gonzalez FJ, and Korzekwa KR (1995) Role of cytochrome P450 2C9 and an allelic variant in the 4′- hydroxylation of (R) and (S)-flurbiprofen. Biochem Pharmacol 49:1269-1275.
22. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, and Hall SD (2001) The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 70:317-326.
23. Wang Z, Hamman MA, Huang S-M, Lesko LJ, and Hall SD (2002) Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 71:414-420.
24. Wheatley D (1997) LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients - a controlled 6-week clinical trial. Pharmacopsychiatry 30 (Suppl 2):77-80.
25. Yue QY, Bergquist C, and Gerden B (2000) Safety of St. John's wort (Letter). Lancet 355:576-577.